LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System. The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

LENSAR Inc.

In a report released yesterday, from BTIG maintained a Hold rating on LENSAR. The company’s shares closed yesterday at $10.45. Currently, the analy...

BTIG Sticks to Its Hold Rating for LENSAR (LNSR)

Lake Street analyst Frank Takkinen reiterated a Hold rating on LENSAR today and set a price target of $15.00. Takkinen covers the Healthcare sector...

Market Cap	$128.40M	P/E Ratio	NaN
52W High	$17.31	52W Low	$7.00
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	0.0%	52W Position	27.4%
Overall Score	24	Value Score	40
Quality Score	--	Technical Score	9

EPS Current Est	$NA	EPS Next Est	$NA
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LNSR	$9.83	+1.34%	32.16K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LNSR	$9.83	+1.3%	32.16K
3
4
5
6

LNSR

LNSR

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get LENSAR Inc. Data in Excel

Get LENSAR Inc. Data in Excel